Fourteen pairs of identical twins joined the EU funded medical project “ Fight-MG ”, to fight Myasthenia Gravis . This rare autoimmune disease leads to abnormal fatigability of various skeletal muscles.

Myasthenia Gravis (MG) is a rare auto-immune disease—whereby patients’ immune systems attack their own bodies— arising from a breakdown in communications between the nervous and muscular systems.

Collaboration between research groups is key in tackling rare diseases such as auto-immune disease Myasthenia Gravis (MG). Indeed, the rarity of the disease means that it can be difficult to collect enough samples of blood and tissues to perform quality research.

We age in two ways. There is the ageing we count by clock and calendar. And then there is biological ageing. The latter is written into our genes. But, it is also influenced by our lifestyle and history.

The impact if this challenge could be huge, as this set of data could l ead to new therapies and diagnosing tools for virtually all diseases , including diabetes or cancer.  Proteins are everywhere.

The human genome and those of several other organisms have been mapped. But it is proteins that perform the majority of biological functions within every organism .

European scientists set up new therapeutic approaches to tackle specific Lysosomal Storage Disorders: a new drug combination and enzyme replacement therapy against Pompe disease and gene therapy against MPS V I (Mucopolysaccharidosis VI).

With a prevalence of about 1 in 10.000, Ataxia is considered a rare hereditary disease that attacks the central nervous system. As a result, it is not at the top of the list in terms of research topics for pharmaceutical companies.

For a neurodegenerative disease that strikes later in life with neuronal dysfunction and subsequent cell death by showing a mind-boggling heterogeneity of subtypes, spinocerebellar ataxia had not been adequately tackled for a long time.